Evidence map›Paper›PMID 38472361›Full record

ArticleAnnals of hematology2024

Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.

Georg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, Hartmut Linde, Andreas Josting, Eyck von der Heyde, Uwe Platzbecker, Rudolf Weide, Hans Tesch, Arndt Nusch and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Georg-Nikolaus FrankeDepartment for Hematology, Cellular Therapies, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany. Georg-nikolaus.franke@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0001-8239-002X
Gunnar LoeweNovartis Pharma GmbH, Nuremberg, Germany.
Marcel ReiserPIOH-Zentrum Praxis Internistischer Onkologie und Hämatologie, Cologne, Germany.
Hartmut LindeMVZ für Blut- und Krebserkrankungen, Potsdam, Germany.
Andreas JostingSchwerpunktpraxis für Onkologie, Gastroenterologie, Hämatologie und Palliativmedizin, Berlin, Germany.
Eyck von der HeydeStudienzentrum am Raschplatz GbR, Hannover, Germany.
Uwe PlatzbeckerDepartment for Hematology, Cellular Therapies, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Rudolf WeidePraxis für Hämatologie und Onkologie, Koblenz, Germany.
Hans TeschCentrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany.
Arndt NuschMVZ-Onkologie Velbert/Ratingen GbR, Velbert, Germany.
Jolanta DenglerOnkologische Schwerpunktpraxis Heilbronn, Heilbronn, Germany.
Kathleen Jentsch-UllrichGemeinschaftspraxis für Hämatologie und Onkologie, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized centers whereas primary care for patients (pts) with CML is mainly provided by local oncology practices. The aim of this study was to assess treatment practices in pts with CML in the setting of private oncology practices in Germany. We collected data of 819 pts with a confirmed diagnosis (dx) of CML in 2013 or later from 43 practices. At dx, 84.2% (n=690) and 9.4% (n=77) of pts were in chronic or accelerated phase, 0.7% (n=6) had a blast crisis. Molecular monitoring was provided by EUTOS certified laboratories in 87.7% of pts. Typical BCR::ABL1 transcripts were detected in 86.6% (n=709). Molecular response was assessed after 2.8, 6.0, 9.4 and 12.9 m (mean) after start of treatment. Of the pts with available data, 11.1% did not achieve early molecular response and at 18 m, 83.7% had at least a major molecular response. 288 (35.2%) of pts switched to 2

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveBlast CrisisFusion Proteins, bcr-ablGermanyHumansProtein Kinase InhibitorsRetrospective StudiesFusion Proteins, bcr-ablProtein Kinase InhibitorsBCR::ABL1Chronic myeloid leukemiareal-world data

Identifiers

PMID38472361
PMCPMC11009736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.